Allianz Asset Management
ACRS icon

Allianz Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Allianz Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,800
Closed -$343K – 2140
2022
Q4 		$343K Hold
21,800
– – ﹤0.01% 1794
2022
Q3 		$343K Sell
21,800
-78,030
-78% -$1.23M ﹤0.01% 1586
2022
Q2 		$1.39M Buy
99,830
+17,865
+22% +$250K ﹤0.01% 1555
2022
Q1 		$1.41M Buy
81,965
+25,125
+44% +$343K ﹤0.01% 1725
2021
Q4 		$825K Hold
56,840
– – ﹤0.01% 1983
2021
Q3 		$1.02M Buy
+56,840
New +$911K ﹤0.01% 1920

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Allianz Asset Management's ACRS Position: Q1 2023 in Review

Allianz Asset Management sold out of Aclaris Therapeutics (ACRS) in Q1 2023, closing a stake of 21,800 shares — an estimated $343K sold.

Allianz Asset Management first reported a position in ACRS in Q3 2021 and held it in 6 quarters. The position peaked at $1.41M in Q1 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q1 2023.

  • Allianz Asset Management reported no remaining Aclaris Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Allianz Asset Management sold 21,800 Aclaris Therapeutics shares in Q1 2023, an estimated $343K.
  • Allianz Asset Management first reported a position in Aclaris Therapeutics in Q3 2021 and held it in 6 quarters.
  • Allianz Asset Management's Aclaris Therapeutics position peaked at $1.41M in Q1 2022.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2023.

Based on Allianz Asset Management's 13F filing for Q1 2023, filed 11 May 2023.